Merck & Co. Inc. stock (US58933Y1055): Q1 earnings beat with revenue growth

Merck & Co. Inc. released its first-quarter 2026 earnings on May 13, 2026, reporting revenue of $16.3 billion, a 5% increase from the prior year, driven by strong oncology sales including Keytruda. The company recorded a non-GAAP loss of $1.28 per share, influenced by acquisition-related costs from the Cidara deal, according to Morningstar as of 05/13/2026. Shares traded at $119.63, up 0.59% on the day.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Merck & Co. Inc.: core business model

Merck & Co. Inc., known as MSD outside the US and Canada, operates as a leading global healthcare company focused on innovative medicines, vaccines, and animal health products. The firm invests heavily in R&D, with a portfolio spanning oncology, immunology, and infectious diseases. Keytruda, its blockbuster PD-1 inhibitor, remains a cornerstone, generating billions in annual sales for cancer treatments.

Merck's business model emphasizes blockbuster drugs and strategic partnerships to extend product lifecycles. The company reported Q1 2026 revenue growth amid a challenging market, highlighting resilience in its pharma segment, per its investor updates as of 05/13/2026.

Main revenue and product drivers for Merck & Co. Inc.

Oncology drives over 40% of revenue, led by Keytruda, which saw continued demand in Q1 2026. Vaccines like Gardasil contributed to growth, while animal health provided stable cash flows. Recent deals, including Keytruda collaborations, bolster future pipelines, as noted in Simply Wall St as of 05/13/2026.

Merck upgraded its 2026 outlook, signaling confidence in sustained growth despite patent cliffs ahead. US market exposure remains critical, with Keytruda holding significant share in immuno-oncology.

Industry trends and competitive position

The pharma sector faces pricing pressures and biosimilar competition, yet oncology innovation propels leaders like Merck. Keytruda's dominance positions Merck favorably against rivals like Bristol Myers Squibb and Roche, with US approvals enhancing market share.

Why Merck & Co. Inc. matters for US investors

Listed on NYSE, Merck offers US investors exposure to a diversified pharma giant with heavy reliance on the US market, where over 50% of sales originate. Its vaccine and oncology portfolios align with aging demographics and healthcare spending trends.

Conclusion

Merck & Co. Inc. demonstrated solid Q1 performance with revenue growth and an upgraded outlook, underscoring strength in core franchises like Keytruda. While acquisition costs impacted earnings, the company's pipeline and US market position support ongoing relevance for investors tracking pharma trends. Market dynamics will shape near-term trading.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.